We are live on ! Find out more
ANTX icon

AN2 Therapeutics
ANTX

18 hedge funds and large institutions have $134M invested in AN2 Therapeutics in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

47.77% more ownership

Funds ownership: 0% → 47.77% (+48%)

Holders
18
Holders Change
+18
Holders Change %
–
% of All Funds
0.28%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
18
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$55.6M
2
BI
BVF Inc
California
+$24.5M
3
Citadel Advisors
Citadel Advisors
Florida
+$21.5M
4
APM
Avidity Partners Management
Texas
+$10.4M
5
DM
Deerfield Management
New York
+$8.86M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$55.3M +$55.6M +3,666,663 New
BI
2
BVF Inc
California
$24.4M +$24.5M +1,616,665 New
Citadel Advisors
3
Citadel Advisors
Florida
$20.6M +$21.5M +1,419,851 New
APM
4
Avidity Partners Management
Texas
$10.4M +$10.4M +688,330 New
DM
5
Deerfield Management
New York
$8.8M +$8.86M +584,136 New
MIM
6
Monashee Investment Management
Massachusetts
$6.53M +$6.57M +433,330 New
WP
7
Woodline Partners
California
$2.26M +$2.28M +150,000 New
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
$1.88M +$1.9M +125,000 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.13M +$1.13M +74,733 New
Millennium Management
10
Millennium Management
New York
$1.12M +$1.13M +74,238 New
CAC
11
Cowen and Company
New York
$908K +$915K +60,278 New
Goldman Sachs
12
Goldman Sachs
New York
$294K +$296K +19,497 New
Barclays
13
Barclays
United Kingdom
$275K +$276K +18,220 New
Wellington Management Group
14
Wellington Management Group
Massachusetts
$250K +$252K +16,600 New
AFM
15
Anson Funds Management
Texas
$38K +$37.9K +2,500 New
UBS Group
16
UBS Group
Switzerland
$17K +$17.6K +1,158 New
Morgan Stanley
17
Morgan Stanley
New York
$14K +$13.4K +885 New
TRCT
18
Tower Research Capital (TRC)
New York
$10K +$9.91K +653 New

ANTX Hedge Fund Activity: Q1 2022 in Review

18 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q1 2022, worth a combined $134M.

Buyers outnumbered sellers: 18 funds opened new ANTX positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $55.6M.

  • 18 institutional investors held AN2 Therapeutics (ANTX) as of Q1 2022, up from 0 in Q4 2021.
  • Funds reported $134M of AN2 Therapeutics stock for Q1 2022.
  • 18 funds opened new AN2 Therapeutics positions in Q1 2022 and 0 closed out, a net change of +18 holders.
  • The largest AN2 Therapeutics buyer in Q1 2022 was RA Capital Management, an estimated $55.6M added.

Based on aggregated 13F filings for Q1 2022.